Ofatumumab, a human anti‐CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease‐modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials
Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
A subcutaneous 30mg dose of Ofatumumab provides 2 months of profound B-cell depletion, without troublesome infusion reactions. If clinical efficacy pans out, RA treatment just became effective, safe, convenient and super-cheap!